A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
Active, not recruiting · NCT04194554 · Registry updated 2026-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-01 | NCT04194554 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Scientific Affairs, LLC | 37 |
| University of Michigan Rogel Cancer Center | 63 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cornell University | New York | United States | 10 |
| Mayo Clinic | Rochester | United States | 22 |
| University Hospitals Seidman Cancer Center | Cleveland | United States | 10 |
| University of Michigan Rogel Cancer Center | Ann Arbor | United States | 186 |
| University of Texas Southwestern | Dallas | United States | 73 |
| Weill Cornell Medicine | New York | United States | 122 |